FGF23 and X-linked dominant hypophosphatemic rickets: Recently, a novel FGF23 antibody (Burosumab) has been approved for the treatment of patients with XLHR.[11, 14] Blockade of FGF23 signaling by burosumab improved hypophosphatemia, 1,25(OH)2D deficiency and skeletal deformities in children and adults with XLHR.